# Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

> **NCT05238324** · PHASE1 · WITHDRAWN · sponsor: **Homology Medicines, Inc**

## Conditions studied

- Mucopolysaccharidosis II

## Interventions

- **BIOLOGICAL:** Genetic HMI-203

## Key facts

- **NCT ID:** NCT05238324
- **Lead sponsor:** Homology Medicines, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-08
- **Primary completion:** 2024-10
- **Final completion:** 2029-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Homology Medicines has discontinued development of this program.
- **Last updated:** 2023-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238324, "Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05238324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*